Plasma growth hormone-binding activity is low in uraemic children.
Plasma growth hormone-binding protein (GH-BP) activity was evaluated in two groups of prepubertal children with chronic renal failure (CRF) who had been treated with recombinant human GH (rhGH). Group 1 consisted of eight children (mean chronological age 10.8 years) with advanced renal failure; group 2 consisted of nine children (mean chronological age 6 years) presenting with end-stage renal disease, who were on dialysis. Before treatment the specific binding of (125I)hGH to high-affinity GH-BP was low in the two groups (group 1, 17.3 +/- 1.6% of radioactivity; group 2, 14.2 +/- 1.4%) compared with the mean value obtained in normal prepubertal children (24.8 +/- 1.7%). No significant changes in GH-BP activity were found during the 1st year of GH therapy, although growth velocity and plasma levels of insulin-like growth factor-I increased significantly in both groups. The low GH-binding activity found in children with CRF supports the state of GH resistance. The reason for the absence of a GH-BP response to GH therapy has to be clarified.
Postel-Vinay
M C
MC
Unité de Biologie et Pathologie de la croissance et du Développement, INSERM U30, Paris, France.
Tar
A
A
Crosnier
H
H
Broyer
M
M
Rappaport
R
R
Tönshoff
B
B
Mehls
O
O
D002352:Carrier Proteins / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D002851:Chromatography, High Pressure Liquid; D005260:Female; D006130:Growth Disorders / Q000188:drug therapy; D013006:Growth Hormone / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood; D008297:Male; D011292:Premedication; D011994:Recombinant Proteins / Q000627:therapeutic use; D014511:Uremia / Q000097:blood*
D002352:Carrier Proteins; D011994:Recombinant Proteins; D013006:Growth Hormone; C051815:somatotropin-binding protein